Enliven Therapeutics Inc. (ELVN)
NASDAQ: ELVN
· Real-Time Price · USD
19.44
0.87 (4.68%)
At close: Sep 26, 2025, 1:13 PM
Company Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene.
The company is based in Boulder, Colorado.
Enliven Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Samuel S. Kintz |
Contact Details
Address: 6200 Lookout Road Boulder, Colorado United States | |
| Website | https://www.enliventherapeutics.com |
Stock Details
| Ticker Symbol | ELVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001672619 |
| CUSIP Number | 29337E102 |
| ISIN Number | US29337E1029 |
| Employer ID | 81-1523849 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Samuel S. Kintz M.B.A. | Co-Founder, Chief Executive Officer, Secretary & Director |
| Anish Patel Pharm.D. | Co-Founder & Chief Operating Officer |
| Benjamin Hohl | Chief Financial Officer & Head of Corporate Development |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2025 | 4 | Filing |
| Sep 25, 2025 | 4 | Filing |
| Sep 23, 2025 | 4 | Filing |
| Sep 19, 2025 | 4 | Filing |
| Sep 10, 2025 | 4 | Filing |
| Aug 29, 2025 | 4 | Filing |
| Aug 21, 2025 | 4/A | [Amend] Filing |
| Aug 21, 2025 | 4 | Filing |
| Aug 20, 2025 | 4 | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |